MX9203294A - Factor de estimulacion de aniquilador natural. - Google Patents

Factor de estimulacion de aniquilador natural.

Info

Publication number
MX9203294A
MX9203294A MX9203294A MX9203294A MX9203294A MX 9203294 A MX9203294 A MX 9203294A MX 9203294 A MX9203294 A MX 9203294A MX 9203294 A MX9203294 A MX 9203294A MX 9203294 A MX9203294 A MX 9203294A
Authority
MX
Mexico
Prior art keywords
natural
annihilador
stimulation factor
factor
stimulation
Prior art date
Application number
MX9203294A
Other languages
English (en)
Inventor
Giorgio Trinchieri
Bice Perussia
Michiko Kobatashi
Steve C Clark
Gordon G Wong
Rodney Hewick
Original Assignee
Genetics Inst
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst, Wistar Inst filed Critical Genetics Inst
Publication of MX9203294A publication Critical patent/MX9203294A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Prostheses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
MX9203294A 1988-11-10 1992-06-25 Factor de estimulacion de aniquilador natural. MX9203294A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26994588A 1988-11-10 1988-11-10
US30781789A 1989-02-07 1989-02-07

Publications (1)

Publication Number Publication Date
MX9203294A true MX9203294A (es) 1992-07-01

Family

ID=26953989

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203294A MX9203294A (es) 1988-11-10 1992-06-25 Factor de estimulacion de aniquilador natural.

Country Status (8)

Country Link
EP (1) EP0441900B1 (es)
JP (3) JP2893653B2 (es)
AT (1) ATE140483T1 (es)
AU (1) AU638430B2 (es)
CA (2) CA2002607C (es)
DE (1) DE68926859T2 (es)
MX (1) MX9203294A (es)
WO (1) WO1990005147A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
ATE366311T1 (de) * 1989-12-22 2007-07-15 Hoffmann La Roche Zytotoxischer lymphozyten-reifefaktor 35kd untereinheit und monoklonale antikörper spezifisch dafür
AU5325694A (en) * 1992-11-25 1994-06-22 Brigham And Women's Hospital Epstein barr virus induced genes
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
DE69620877T2 (de) * 1995-02-06 2002-12-12 Genetics Inst Arzneimittelformulierungen für il-12
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US5652224A (en) * 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
AU724743B2 (en) 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
EP0931156A2 (en) * 1996-10-18 1999-07-28 Valentis Inc. Gene expression and delivery systems and uses
CA2268365A1 (en) * 1996-10-18 1998-04-30 Jeff Nordstrom Il-12 gene expression and delivery systems and uses
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
WO1998041229A1 (en) * 1997-03-19 1998-09-24 F. Hoffmann-La Roche Ag USE OF IL-12p40 AS IMMUNOSTIMULANT
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
WO2000015249A1 (en) 1998-09-15 2000-03-23 Genetics Institute, Inc. Treatment of kaposi's sarcoma with il-12
US6375944B1 (en) 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
TR200103266T2 (tr) 1999-05-13 2002-01-21 American Cyanamid Company Yardımcı kombinasyon formülasyonları
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
JP2002045174A (ja) * 2000-07-31 2002-02-12 Inst Of Physical & Chemical Res ナチュラルキラー細胞増殖法
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
EE200300172A (et) 2000-11-10 2003-06-16 Wyeth Holdings Corporation Antigeenne kompositsioon ja adjuvantsegu
WO2004014947A1 (en) * 2002-08-06 2004-02-19 Aventis Pharma Deutschland Gmbh Method for isolating an intestinal cholesterol binding protein
CN101120087A (zh) 2004-12-21 2008-02-06 森托科尔公司 抗-il-12抗体、表位、组合物、方法和用途
US9849087B2 (en) 2011-11-08 2017-12-26 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
US10765724B2 (en) 2016-03-29 2020-09-08 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3793521A4 (en) 2018-05-18 2022-02-23 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
CA3113837C (en) 2018-09-24 2022-07-12 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473555A (en) * 1983-10-17 1984-09-25 Syntex (U.S.A.) Inc. Nona- and dodecapeptides for augmenting natural killer cell activity
US5185431A (en) * 1988-08-31 1993-02-09 Eisai Co., Ltd. Recombinant natural killer cell activator

Also Published As

Publication number Publication date
DE68926859D1 (de) 1996-08-22
WO1990005147A1 (en) 1990-05-17
DE68926859T2 (de) 1997-02-13
JP2001245678A (ja) 2001-09-11
CA2002607A1 (en) 1990-05-10
JP2893653B2 (ja) 1999-05-24
JPH11215993A (ja) 1999-08-10
AU638430B2 (en) 1993-07-01
EP0441900B1 (en) 1996-07-17
ATE140483T1 (de) 1996-08-15
JP3261124B2 (ja) 2002-02-25
CA2002607C (en) 2004-01-27
EP0441900A1 (en) 1991-08-21
AU4667389A (en) 1990-05-28
CA2441636A1 (en) 1990-05-10
JPH04502151A (ja) 1992-04-16

Similar Documents

Publication Publication Date Title
MX9203294A (es) Factor de estimulacion de aniquilador natural.
DK203187A (da) Human g-csf proteinekspression
ZA872705B (en) Human g-csf protein expression
IT8812558A0 (it) Poltrona per abbronzatura
DE3777253D1 (de) Herzschrittmacher zur stimulierung des menschlichen herzens.
NO880193D0 (no) Vevveksthjelpemiddel og fremstilling derav.
EP0245433A4 (en) MAIN PROTEIN WITH FERRIC REGULATION OF NEISSERIA GONORRHEA AND ITS USE AS A VACCINE.
DE69008664D1 (de) Bestrahlung von bluterzeugnissen.
DK551187A (da) Terapeutisk praeparat og dettes fremstilling
KR890700608A (ko) 사람 인터루킨-3 및 이의 뮤테인
DE3682229D1 (de) Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate.
DE3778585D1 (de) Herzschrittmacher zur stimulierung des menschlichen herzens.
DK13990D0 (da) Superaktive humane insulinanaloge
DE3778587D1 (de) Herzschrittmacher zur stimulierung des menschlichen herzens.
GEP20012571B (en) New Application of Lyzocyme Dimer
DK444288D0 (da) Humant reg - protein
IT1226386B (it) Procedimento di preparazione di morniflumato e analoghi.
DK590987D0 (da) Peptid og farmaceutisk praeparat indeholdende et saadant peptid
DK0425001T3 (da) Naturlige delta-lactoner og fremgangsmåde til fremstilling deraf
FR2638747B1 (fr) Derives de phenyloxypropanolamines, leur preparation et leur application en therapeutique
DK173886D0 (da) 1-hydroxy-8-acyloxy-10-acyl-anthroner, deres fremstilling og deres anvendelse til human- eller veterinaermedicinske og kosmetiske formaal
IL79791A0 (en) 5-esters of milbemycins,their preparation and their use for controlling parasitic pests
IT8619457A1 (it) Derivati insaturi cicloalifatici, loro procedimenti di preparazione e loro impiego in terapia e in cosmetica
LV10393A (lv) Savietojams cilveka olbaltumvielas preparats
DK0427633T3 (da) Anvendelse af et polypeptid med gammainterferonaktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af primitiv pleuracancer